School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, China; Guangdong Engineering Research Center for Lead Compounds & Drug Discovery, Guangzhou, 510006, China.
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China.
J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117265. doi: 10.1016/j.jep.2023.117265. Epub 2023 Sep 30.
Wedelia (Sphagneticola trilobata) is a traditional anti-inflammatory herb native to tropical America. It is commonly used to treat some inflammatory related diseases clinically, such as pertussis, pharyngitis, etc. However, its specific anti-inflammatory mechanism is still unclear.
WT-29 (3α-angeloyloxy-9β-hydroxyent-kaura-16-en-19-oic acid) is a main bioactive diterpenoid isolated and purified from Wedelia. This study aims to explore the potential anti-inflammatory and anti-allergic properties of WT-29 on RAW264.7 cells stimulated with LPS and P815 cells induced by C48/80, as well as investigating their underlying molecular mechanisms.
The anti-inflammatory mechanism of WT-29 was analyzed and predicted using network pharmacology, and then verified through experiments. The Griess reagent assay was employed to evaluate the impact of WT-29 on the generation of nitric oxide (NO) in RAW264.7 cells induced by LPS, the expression of various inflammatory cytokines and the release of histamine in cells were measured through qRT-PCR and ELISA techniques. The impact of WT-29 on the translocation of the NF-κB p65 protein to the nucleus was assessed through immunofluorescence staining. Western blot technique was utilized to investigate protein expression in inflammation, allergy, and autophagy pathways.
The study found that WT-29 can reduce the secretion of inflammatory factors (NO, iNOS, COX-2, IL-6, IL-1β and TNF-α), inhibit NF-κB activation and MAPK family phosphorylation, and induce autophagy in RAW264.7 cells stimulated with LPS. In addition, it demonstrated that WT-29 could inhibit histamine release and degranulation, as well as inhibit the MAPK family in C48/80-induced P815 cells.
WT-29 isolated from Wedelia exerts anti-inflammatory and anti-allergic effects mainly through NF-κB, Nrf2/Keap-1, MAPK pathways and regulating of autophagy, suggesting that it might be a potential anti-inflammatory and anti-allergic agent and could be used as medicine or health benefit product.
三叶鬼针草(Sphagneticola trilobata)是一种原产于热带美洲的传统抗炎草药。临床上常用于治疗百日咳、咽炎等一些炎症相关疾病。但其具体的抗炎机制尚不清楚。
WT-29(3α-angeloyloxy-9β-hydroxyent-kaura-16-en-19-oic acid)是从三叶鬼针草中分离纯化得到的主要生物活性二萜。本研究旨在探讨 WT-29 对 LPS 刺激的 RAW264.7 细胞和 C48/80 诱导的 P815 细胞的潜在抗炎和抗过敏特性,并研究其潜在的分子机制。
采用网络药理学方法分析和预测 WT-29 的抗炎机制,然后通过实验进行验证。采用 Griess 试剂法检测 WT-29 对 LPS 诱导的 RAW264.7 细胞中一氧化氮(NO)生成的影响,通过 qRT-PCR 和 ELISA 技术检测 WT-29 对细胞中各种炎症因子表达和组胺释放的影响。采用免疫荧光染色法检测 WT-29 对 NF-κB p65 蛋白核转位的影响。Western blot 技术用于研究炎症、过敏和自噬途径中的蛋白表达。
研究发现,WT-29 可降低 LPS 刺激的 RAW264.7 细胞中炎症因子(NO、iNOS、COX-2、IL-6、IL-1β 和 TNF-α)的分泌,抑制 NF-κB 激活和 MAPK 家族磷酸化,并诱导自噬。此外,它表明 WT-29 可以抑制组胺释放和脱颗粒,以及抑制 C48/80 诱导的 P815 细胞中的 MAPK 家族。
从三叶鬼针草中分离得到的 WT-29 主要通过 NF-κB、Nrf2/Keap-1、MAPK 通路和调节自噬发挥抗炎和抗过敏作用,提示其可能是一种有潜力的抗炎和抗过敏药物,可作为药物或保健品使用。